In conclusion, the exploration of GITR signaling in HCC underscores its use as a promising therapeutic target, potentially being included in the avenues for precise therapeutic interventions arising from the interplay between the immune system and the HCC TME. Here, TNFRSF18 is linked to hepatocellular carcinoma.